EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis

Xiaoyu Xu iD, Yuzheng Fang, Qirui Wang, Shuanfeng Zhai, Wanshan Liu, Wanwan Liu, Ruimin Wang, Qiuqiong Deng, Juxiang Zhang, Jingli Gu, Yida Huang, Dingyitai Liang und 8 weitere

Advanced Science · 2024-09 · 11 (34)

DOI: 10.1002/advs.202401919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 08.07.2024. Verfasst von Xiaoyu Xu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Shanghai Jiao Tong University Inner Mongolia Research Institute, Shanghai Institutions of Higher Learning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) is a substantial pathology of the urinary system with a growing prevalence rate. However, current clinical methods have limitations for managing RCC due to the heterogeneity manifestations of the disease. Metabolic analyses are regarded as a preferred noninvasive approach in clinics, which can substantially benefit the characterization of RCC. This study constructs a nanoparticle‐enhanced laser desorption ionization mass spectrometry (NELDI MS) to analyze metabolic fingerprints of renal tumors ( n = 456) and healthy controls ( n = 200). The classification models yielded the areas under curves (AUC) of 0.938 (95% confidence interval (CI), 0.884–0.967) for distinguishing renal tumors from healthy controls, 0.850 for differentiating malignant from benign tumors (95% CI, 0.821–0.915), and 0.925–0.932 for classifying subtypes of RCC (95% CI, 0.821–0.915). For the early stage of RCC subtypes, the averaged diagnostic sensitivity of 90.5% and specificity of 91.3% in the test set is achieved. Metabolic biomarkers are identified as the potential indicator for subtype diagnosis ( p < 0.05). To validate the prognostic performance, a predictive model for RCC participants and achieve the prediction of disease ( p = 0.003) is constructed. The study provides a promising prospect for applying metabolic analytical tools for RCC characterization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsBiomarkers, TumorHumansMaleFemaleMiddle AgedPrognosisAgedAdultSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationEarly Detection of Cancer

Stichwörter der Autor:innen

mass spectrometrymetabolic fingerprintingprognosisrenal diagnosissubtype classification

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Urology, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, P. R. China.
  • State Key Laboratory of Systems Medicine for Cancer, School of Biomedical Engineering and Institute of Medical Robotics, Shanghai Jiao Tong University, Shanghai, 200030, P. R. China.
  • Division of Cardiology, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.
  • Health Management Center, Renji Hospital, School of Medicine in Shanghai Jiao Tong University, Shanghai, 200127, P. R. China.

ORCID-Profile: Xiaoyu Xu, Kun Qian, Wei Zhai

Förderung

  • National Key Research and Development Program of China
  • Shanghai Jiao Tong University Inner Mongolia Research Institute
  • Shanghai Institutions of Higher Learning
  • Science and Technology Commission of Shanghai Municipality
  • Shanghai Municipal Health Commission
  • Guangdong Provincial Introduction of Innovative Research and Development Team
  • Innovative Research Group Project of the National Natural Science Foundation of China
  • Joint Laboratory of Precision Engineering

Zitieren

APA

Xu, X., Fang, Y., Wang, Q., Zhai, S., Liu, W., Liu, W., Wang, R., Deng, Q., Zhang, J., Gu, J., Huang, Y., Liang, D., Yang, S., Chen, Y., Zhang, J., Xue, W., Zheng, J., Wang, Y., Qian, K., & Zhai, W. (2024). Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis. Advanced Science, 11(34). https://doi.org/10.1002/advs.202401919

Vancouver

Xu X, Fang Y, Wang Q, Zhai S, Liu W, Liu W, et al. Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis. Advanced Science. 2024;11(34). doi:10.1002/advs.202401919

BibTeX
@article{Xu2024,
  author = {Xu, Xiaoyu and Fang, Yuzheng and Wang, Qirui and Zhai, Shuanfeng and Liu, Wanshan and Liu, Wanwan and Wang, Ruimin and Deng, Qiuqiong and Zhang, Juxiang and Gu, Jingli and Huang, Yida and Liang, Dingyitai and Yang, Shouzhi and Chen, Yonghui and Zhang, Jin and Xue, Wei and Zheng, Junhua and Wang, Yuning and Qian, Kun and Zhai, Wei},
  title = {Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis},
  journal = {Advanced Science},
  year = {2024},
  volume = {11},
  number = {34},
  doi = {10.1002/advs.202401919}
}
Kostenlos starten →